NASDAQ:WVE - Wave Life Sciences Stock Price, Forecast & News

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Wave Life Sciences Ltd (NASDAQ:WVE) released its quarterly earnings results on Tuesday, November, 5th. The company reported ($1.48) EPS for the quarter, missing analysts' consensus estimates of ($1.34) by $0.14. The company had revenue of $2.93 million for the quarter, compared to the consensus estimate of $6.30 million. Wave Life Sciences had a negative return on equity of 128.21% and a negative net margin of 1,015.84%. View Wave Life Sciences' Earnings History.

Wave Life Sciences is scheduled to release their next quarterly earnings announcement on Friday, March 6th 2020. View Earnings Estimates for Wave Life Sciences.

8 analysts have issued 12-month price objectives for Wave Life Sciences' stock. Their forecasts range from $10.00 to $65.00. On average, they anticipate Wave Life Sciences' share price to reach $25.00 in the next twelve months. This suggests a possible upside of 217.3% from the stock's current price. View Analyst Price Targets for Wave Life Sciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Wave Life Sciences.

Headlines about WVE stock have been trending very negative on Saturday, InfoTrie reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Wave Life Sciences earned a coverage optimism score of -3.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Wave Life Sciences.

Wave Life Sciences saw a increase in short interest in December. As of December 31st, there was short interest totalling 4,400,000 shares, an increase of 26.1% from the December 15th total of 3,490,000 shares. Based on an average trading volume of 793,000 shares, the short-interest ratio is presently 5.5 days. Approximately 16.9% of the company's shares are short sold. View Wave Life Sciences' Current Options Chain.

Some companies that are related to Wave Life Sciences include Rocket Pharmaceuticals (RCKT), Opko Health (OPK), Phibro Animal Health (PAHC), Dermira (DERM), IGM Biosciences (IGMS), XBiotech (XBIT), Revance Therapeutics (RVNC), RAPT Therapeutics (RAPT), Gossamer Bio (GOSS), G1 Therapeutics (GTHX), Amphastar Pharmaceuticals (AMPH), Odonate Therapeutics (ODT), Akebia Therapeutics (AKBA), Radius Health (RDUS) and Rhythm Pharmaceuticals (RYTM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Exelixis (EXEL), Gilead Sciences (GILD), Novavax (NVAX), TherapeuticsMD (TXMD), GW Pharmaceuticals PLC- (GWPH), SAGE Therapeutics (SAGE), Portola Pharmaceuticals (PTLA), Canopy Growth (CGC), bluebird bio (BLUE) and Cidara Therapeutics (CDTX).

Wave Life Sciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.20%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc. View Institutional Ownership Trends for Wave Life Sciences.

WVE stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. View Insider Buying and Selling for Wave Life Sciences.

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of WVE stock can currently be purchased for approximately $7.88.

Wave Life Sciences has a market capitalization of $270.21 million and generates $14.41 million in revenue each year. The company earns $-146,650,000.00 in net income (profit) each year or ($5.06) on an earnings per share basis. Wave Life Sciences employs 250 workers across the globe.View Additional Information About Wave Life Sciences.

The official website for Wave Life Sciences is http://www.wavelifesciences.com/.

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]